21:53 , Jun 11, 2019 |  BC Innovations  |  Distillery Therapeutics

PSEN1 inhibition could treat T cell ALL

DISEASE CATEGORY: Cancer INDICATION: Acute lymphoblastic leukemia (ALL) Cell culture and mouse studies suggest inhibiting PSEN1 could help treat T cell ALL. In two human T cell ALL cell lines, a tool compound PSEN1 inhibitor...
01:42 , May 4, 2019 |  BioCentury  |  Product Development

How the amyloid hypothesis holds its grip

By now, two things are clear about the amyloid hypothesis of Alzheimer’s disease: one is that the amyloid peptide is somehow involved; the other is that it’s a terrible target. β amyloid has had an...
20:18 , Mar 25, 2019 |  BC Innovations  |  Distillery Therapeutics

Inhibiting EFR3A to treat Alzheimer's disease

DISEASE CATEGORY: Neurology INDICATION: Alzheimer's disease (AD) Mouse studies suggest inhibiting EFR3A could help treat AD. In a transgenic mouse model of AD expressing mutant human amyloid precursor protein (APP) and presenilin 1 (PSEN1; PS1),...
13:26 , Jan 30, 2019 |  BC Innovations  |  Distillery Therapeutics

Neurology; cardiovascular

INDICATION: Alzheimer's disease (AD); atherosclerosis Mouse studies suggest inhibiting C5 could help treat AD and atherosclerosis. In a transgenic mouse model of AD expressing mutant human amyloid precursor protein (APP) and presenilin 1 (PSEN1; PS1),...
03:36 , Jan 4, 2019 |  BC Innovations  |  Tools & Techniques

Making AD mice as diverse as patients

The Jackson Laboratory aims to make Alzheimer’s disease mouse models more useful for predicting which patients will respond to therapy by engineering in a high degree of genetic diversity to better reflect trial populations. The...
13:28 , Dec 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer's disease (AD) In vitro and mouse studies identified an inhibitor of Aβ 42 polymerization that could help treat AD. In vitro screening of nine amyloid-binding compounds in polymerization assays, followed by in vitro...
18:51 , Nov 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD) Cell culture and mouse studies suggest inhibiting HDAC3 could help treat AD. In a HEK cell line expressing mutant APP, a tool compound HDAC3 inhibitor decreased levels of neurotoxic β amyloid...
17:50 , May 16, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD) In vitro and mouse studies suggest a peptide-based agent that captures Aβ 42 and induces autophagy could help treat AD. The “nanosweeper” agent consists of a PEGylated GKLVFF peptide that binds...
22:03 , Oct 6, 2017 |  BC Extra  |  Preclinical News

New light on gamma secretase failures in AD

In a study published in Cell Reports this week, researchers from Osaka University added another possible explanation for why gamma secretase /presenilin inhibitors have failed in Alzheimer’s disease trials. The gamma secretase complex acts downstream...
15:53 , Mar 28, 2017 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Transgenics and knockouts A transgenic and chimeric brain mouse model of AD could be used to screen therapies for the disease. The model was generated by transplanting human cortical precursor cells derived from pluripotent...